GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (LSE:VRCI) » Definitions » Capital Expenditure

Verici Dx (LSE:VRCI) Capital Expenditure : £-0.17 Mil (TTM As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Verici Dx Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Verici Dx's cash flow for capital expenditures for the six months ended in Jun. 2024 was £-0.08 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Jun. 2024 was £-0.17 Mil.

Verici Dx Capital Expenditure Historical Data

The historical data trend for Verici Dx's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx Capital Expenditure Chart

Verici Dx Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Capital Expenditure
- -0.73 -1.07 -0.18

Verici Dx Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Capital Expenditure Get a 7-Day Free Trial -0.59 -0.48 -0.08 -0.10 -0.08

Verici Dx Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-0.17 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Verici Dx Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (LSE:VRCI) » Definitions » Capital Expenditure
Comparable Companies
LSE:ABDX LSE:GDR LSE:GENI LSE:PRM LSE:LLAI LSE:AGL TMO DHR SHSE:603259 IQV IDXX A XSWX:LONN MTD ICLR LH ILMN DGX WAT EXAS
Traded in Other Exchanges
VRCDF:USA
Address
19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ
Website
https://www.vericidx.com
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies that will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx Headlines

No Headlines